Identification of Compound CB-2 as a Novel Late-Stage Autophagy Inhibitor Exhibits Inhibitory Potency against A549 Cells

Identification of Compound CB-2 as a Novel Late-Stage Autophagy Inhibitor Exhibits Inhibitory Potency against A549 Cells

Autophagy has been recognized as a stress tolerance mechanism that maintains cell viability, which contributes to tumor progression, dormancy, and treatment resistance. The inhibition of autophagy in cancer has the potential to improve the therapeutic efficacy. It is therefore of great significance...

Full description

Bibliographic Details
Main Authors: Zhihui Liu, Lu Zhang, Yachao Liu, Hanxiao Zhang, Jingxuan Chen, Gaoqing Feng, Peichang Yang, Fangfang Sha, Liuqing Cui, Gangchun Sun
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Life
Subjects:
non-small cell lung cancer
autophagy inhibitor
(E)-3-((E)-4-chlorobenzylidene)-5-((5-methoxy-1H-indol-3-yl)methylene)-1-methylpiperidin-4-one
reactive oxygen species
Online Access:https://www.mdpi.com/2075-1729/11/8/865

Internet

https://www.mdpi.com/2075-1729/11/8/865

Similar Items